In December, Morgan Stanley co-led a $15.3m series E preferred stock round of financing into NanoString Technologies.
NanoString Technologies, a US-based developer of molecular diagnostic products and tools for translational research, plans to raise $86.25m in its flotation on the Nasdaq stock exchange.
Investment banks JP Morgan and Morgan Stanley are lead underwriters to NanoString, which had a $17.7m net loss on nearly $23m in revenue last year.
In December, Morgan Stanley co-led a $15.3m series E preferred stock round of financing into NanoString Technologies with investment management company Alliance Bernstein. There were also investments from return backers Clarus Ventures…
